John A. Orwin - 08 May 2024 Form 4 Insider Report for Travere Therapeutics, Inc. (TVTX)

Reporting relationship: Director
Issuer ticker: TVTX
Reported as of: 08 May 2024
Net transaction value: $0
SEC form: 4
Accepted by SEC: 10 May 2024, 16:06:03 UTC
Prior SEC filing: 17 Apr 2024
Next SEC filing: 06 Jun 2024
Source filing: View source filing
Reporting owner signature: /s/ Elizabeth E. Reed, Attorney-in-Fact

Key filing fact

John A. Orwin filed Form 4 for Travere Therapeutics, Inc. (TVTX) on 10 May 2024.

Key facts

This page summarizes John A. Orwin's Form 4 filing for Travere Therapeutics, Inc. (TVTX).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 10 May 2024, 16:06.

Change

Previous filing in this sequence was filed on 17 Apr 2024.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

TVTX transaction

Common Stock

Award

Transaction value: $0
Shares: +6,500
Change %: +29%
Price: $0.000000
Shares after: 28,875
Date: 08 May 2024
Ownership: Direct
Footnotes: F1, F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

TVTX transaction Derivative

Stock option (right to buy)

Award

Transaction value: $0
Shares: +19,500
Change %
Price: $0.000000
Shares after: 19,500
Date: 08 May 2024
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 19,500
Exercise price: $6.82
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program.

Footnote F2

The equity award vests over a one year period.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. to update or revoke optional consent for future visits. For more information, see our Privacy Policy .